证券代码：000915 证券简称：华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：000915 证券简称：华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 编号：2022-001 | --- | --- | --- | |----------------|----------------------------------|---------------------------------------------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他 | | | 光大证券 林小伟 黄素青 | 招商信诺 詹孝颖 | | | 兴证资管 | 刁举鹏 喜世润投资 张北亚 | | | 万家基金 | 杨梦朝 泰康基金 刘勍 | | 参与单位名称及 | 太平基金 | 闫庚威 睿骏资产 魏志华 | | 人员姓名 | 融通基金 杨有为 | 人寿资产 邓文强 | | | 聚铭基金 | 王广群 汇华资本 张桂柱 | | | 嘉 ...

证券代码：000915 证券简称：华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 编号：2022-011 | --- | --- | --- | --- | |-----------------------------|------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------------| | | | | | | | 特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | □其他 | | | | 光大证券组织的电话会议。参加人员主要如下： | | | | | 光大证券：杜传文 林小伟 | 黄素青 | lygh capital ：阙振洋 | | | 博时基金：张弘 工银瑞信：张杭 光 ...

1 证券代码：000915 证券简称：华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 编号：2022-010 | --- | --- | --- | --- | --- | --- | |----------------|--------------------------------------------|-------------|------------|---------------------------------------------|----------------| | | | | | | | | 投资者关系活动 | 特定对象调研 | | | □分析师会议 | | | | □媒体采访 | | | □业绩说明会 | | | 类别 | □新闻发布会 | | | □路演活动 | | | | □现场参观 | | □其他 | | | | | 兴业证券组织的电话会议。参加人员主要如下： | | | | | | | | | | 兴业证券 孙媛媛、董晓洁 中国民生信托 景莹 | | | | 真脉 | Iris Wang、 | Lisa Jiang | 易米基金 刘梦杨、包丽华 | | | | ...

编号：2022-014 证券代码：000915 证券简称：华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|-----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | □特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n 业绩说明会 \n□路演活动 \n 其他 | | 参与单位名称及 人员姓名 | 参加山东辖区上市公司 资者 | 2022 年度投资者网上集体接待日的投 | | 时间 | 2022 年 11 月 16 日 | 14:00-16:00 | | 方式 | 全景网"投资者关系互动平台"（ | https://ir.p5w.net ） | | 上市公司 ...

证券代码：000915 证券简称：华特达因 公告编号：2022-031 山东华特达因健康股份有限公司 关于参加山东辖区上市公司 2022 年度投资者网上集 体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 为加强与广大投资者的沟通交流，山东华特达因健康股份有限 公司（以下简称"公司"）将参加由山东证监局、山东上市公司协会 联合举办的山东辖区上市公司 2022 年度投资者网上集体接待日活 动，现将有关事项公告如下： 一、 活动时间 2022 年 11 月 16 日（星期三）14:00 至 16:00。 二、活动方式 本次投资者网上集体接待日活动将通过全景路演平台进行线上 交 流 。 投 资 者 可 以 登 录 全 景 网 " 投 资 者 关 系 互 动 平 台 " （http://ir.p5w.net/）参与本次活动。 三、公司出席本次活动人员 董事会秘书范智胜先生、财务总监王伟女士、会计机构负责人刘 稳女士、证券事务代表王春阳先生将参加本次投资者网上集体接待日 活动，与投资者进行在线交流。欢迎广大投资者积极参与。 特此公告 山东华特达因健康股 ...

证券代码：000915 证券简称：华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 编号：2022-013 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|----------------------------------------------------|--------------|-------|-----------------------------------------------|-------|--------| | 投资者关系活动 \n类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | \n \n | | □分析师会议 \n□业绩说明会 \n□路演活动 \n□其他 | | | | | | | | 国海证券组织的电话会议。参加人员主要如下： | | | | | 国海证券 | 周小刚、郭磊 | | | | | | | 安信基金 | 英正达 | | 北京诺昌投资 | | 许耀文 | | | 博道基金 | 邓韵阳 | | 北京远惟投资 | | 张翠双 | | | | | ...

Financial Performance - In the first three quarters of 2022, the company achieved a revenue of 1.605 billion CNY, with a net profit of 485.2 million CNY, representing a year-on-year growth of 15.67% and 45.10% respectively [2] - The revenue for the third quarter was 1.819 billion CNY, with a year-on-year growth of 35% [2] - The revenue for the first three quarters of 2022 was 534 million CNY, 545 million CNY, and 526 million CNY respectively, showing a slight decrease in the third quarter compared to the previous two [3] Market Strategy - The company has expanded its target market for its product "Yikexin" from ages 0-3 to 0-6, increasing the potential customer base by 1.5 times [3] - The online sales channel is primarily driven by the pink packaging, while the green packaging is also experiencing growth despite a declining birth rate [4] Cost Management - The company's expense ratio decreased by 3% in the third quarter compared to the first half of the year, attributed to significant revenue growth diluting fixed costs [3] - The gross profit margin remains stable at around 80%, with no significant changes expected in the near future [3] Product Development - The company is focusing on technological innovation and has made progress in building innovation platforms to lead sustainable high-quality development [2] - Research and development expenses are expected to remain stable, aligned with the company's strategic goals [4] Sales Channels - The sales distribution is approximately 15% from hospitals and 85% from outside hospitals, with online penetration around 15-20% [3] - The company is cautious about external investments and currently has no clear acquisition plans [4] Future Outlook - The company anticipates maintaining a revenue growth rate of around 30% in the coming years, supported by new product promotions [3] - The company is prepared to adapt its marketing strategies in response to market changes and competitive pressures [4]

Financial Performance - For the first nine months of 2022, the company achieved a revenue of CNY 1.819 billion, representing a year-on-year growth of 15.67%[5] - The net profit attributable to shareholders for the same period was CNY 462 million, an increase of 45.10% compared to the previous year[5] - The subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd., reported a revenue of CNY 526 million in Q3 2022, up 33.58% year-on-year, and a net profit of CNY 283 million, which is a 68.83% increase[5] - The net profit for the first nine months was CNY 865 million, a 46.22% increase driven by growth in the pharmaceutical business[15] - The net profit for the third quarter was 865,038,482.33 CNY, an increase of 46.1% compared to 591,605,152.82 CNY in the same period last year[30] - The total comprehensive income attributable to the parent company's owners was 462,412,455.71 CNY, compared to 318,686,318.58 CNY in the previous year, reflecting a growth of 45%[30] - The company reported a total profit of 1,009,123,751.74 CNY, up from 693,224,944.16 CNY year-over-year, representing a 45.5% increase[30] Assets and Liabilities - The total assets of the company at the end of the reporting period reached CNY 4.595 billion, a growth of 16.76% from the end of the previous year[7] - Total liabilities rose to CNY 666,435,393.06, compared to CNY 536,028,235.88, marking an increase of 24.3%[26] - The equity attributable to shareholders increased to CNY 2.520 billion, reflecting a year-on-year growth of 12.25%[7] - The equity attributable to shareholders increased to CNY 2,519,636,676.14 from CNY 2,244,689,408.43, a growth of 12.2%[26] - The company's retained earnings reached CNY 2,094,102,952.03, up from CNY 1,819,155,684.32, reflecting an increase of 15.1%[26] Cash Flow and Investments - The net cash flow from operating activities for the first nine months was CNY 945 million, showing a growth of 55.40% year-on-year[7] - Cash flow from operating activities generated a net amount of 945,513,109.09 CNY, compared to 608,444,452.56 CNY in the same period last year, indicating a 55.4% increase[33] - Investment activities resulted in a net cash outflow of 98,191,382.59 CNY, an improvement from a net outflow of 962,673,685.57 CNY in the same period last year[36] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,742[16] - Shandong Huate Holding Group Co., Ltd. holds 22.00% of shares, totaling 51,544,340 shares[16] - Hong Kong Central Clearing Limited holds 3.03% of shares, totaling 7,106,965 shares[16] - The company has a total of 10 major shareholders, with the top 10 holding significant stakes[16] - The company has not reported any pledged or frozen shares among the top shareholders[16] - The report indicates no known relationships or concerted actions among the major shareholders[19] Operational Highlights - Total operating revenue for the third quarter was CNY 1,818,732,732.71, an increase of 15.7% compared to CNY 1,572,409,826.06 in the same period last year[26] - Total operating costs decreased to CNY 831,485,865.51 from CNY 906,185,041.84, representing a reduction of approximately 8.2%[26] - The company reported a significant increase in accounts receivable by 70.73% to CNY 101 million, attributed to the growth in sales revenue[12] - The company’s contract liabilities rose by 73.88% to CNY 190 million, indicating an increase in advance payments received[15] - The company reported a significant increase in accounts payable, which rose to CNY 32,729,985.06 from CNY 70,563,649.54, indicating a decrease of 53.7%[23] Future Plans - The company has plans for market expansion and new product development, although specific figures were not disclosed in the report[28] Earnings Per Share - The basic earnings per share for Q3 2022 was CNY 0.67, marking a 76.36% increase compared to the same period last year[7] - Basic and diluted earnings per share were both 1.97 CNY, up from 1.36 CNY year-over-year[32]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,225,199,135.70, representing a 21.15% increase compared to CNY 1,011,340,076.40 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was CNY 304,643,012.93, up 32.90% from CNY 229,228,221.75 in the previous year[25]. - The net cash flow from operating activities reached CNY 604,737,351.83, a significant increase of 79.03% compared to CNY 337,780,624.10 in the same period last year[25]. - Basic earnings per share increased to CNY 1.30, reflecting a growth of 32.65% from CNY 0.98 in the previous year[25]. - The gross profit margin for the pharmaceutical products segment improved by 1.65 percentage points to 87.08%, with revenue from pharmaceutical products increasing by 44.10% year-on-year[54]. - The company reported a significant increase in revenue from its subsidiary, achieving ¥1,078,872,408.44 in operating income, a 44.10% increase year-on-year[70]. - Net profit from the subsidiary reached ¥548,149,261.31, reflecting a 39.85% growth compared to the same period last year[70]. - The company reported a significant increase in cash flow from operating activities, amounting to CNY 604,737,351.83, a 79.03% increase from CNY 337,780,624.10 in the previous year, attributed to higher sales collections[51]. Assets and Liabilities - The total assets of the company at the end of the reporting period were CNY 4,232,886,535.35, which is a 7.56% increase from CNY 3,935,426,876.64 at the end of the previous year[25]. - The total current assets as of June 30, 2022, amounted to CNY 2,707,741,547.42, an increase from CNY 2,411,163,790.74 on January 1, 2022, reflecting a growth of approximately 12.3%[144]. - Total liabilities rose to ¥598,792,681.73, compared to ¥536,028,235.88, indicating an increase of about 11.7%[150]. - The company's equity attributable to shareholders rose to ¥2,361,867,233.36 from ¥2,244,689,408.43, an increase of approximately 5.2%[150]. - The total owner's equity reached ¥3,634,093,853.62, up from ¥3,399,398,640.76, indicating an increase of approximately 6.9%[150]. Research and Development - The company increased its R&D investment to CNY 35,406,415.39, which is an 18.71% rise from CNY 29,827,217.69 in the previous year, reflecting a commitment to enhancing its product offerings[51]. - The company has established a children's drug research center and has completed five major pediatric drug development tasks under the national "13th Five-Year" plan[42]. - Dain Pharmaceutical has focused on the pediatric pharmaceutical and health industry since 2007, aiming to enhance its competitive advantage in this field[76]. - The company has established a Children's Drug Technology Center in Rongcheng and a Children's Drug Research Institute in Beijing to enhance R&D capabilities[76]. Market and Product Development - The company's main business is in the pharmaceutical sector, with revenue from the pharmaceutical industry amounting to 1.079 billion CNY, accounting for 88.06% of total revenue[33]. - The product line includes well-known brands such as "Yikexin," which has maintained the highest market share in its category for many years[33]. - The company has implemented a brand extension strategy to expand its children's health product chain, including health foods and supplements[33]. - The pediatric health products include various formulations such as oral liquids, granules, and topical ointments, tailored for children's needs[33]. - The company has expanded the usage age of "Yike Xin" vitamin AD from 0-3 years to 0-6 years, further increasing market potential[42]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company aims to enhance its market presence through professional market operations and a nationwide sales network[33]. - Market expansion efforts are underway, with plans to enter H markets by the end of the year, targeting an increase in market share by J%[36]. - Strategic partnerships have been established with M, expected to enhance distribution channels and increase sales by N%[36]. - The company is focusing on sustainability initiatives, committing $O million to improve environmental impact and reduce carbon footprint[36]. Challenges and Risks - In the first half of 2022, the company faced challenges due to the COVID-19 pandemic but managed to achieve record high performance through strategic planning and employee motivation[42]. - The company faces challenges in pediatric pharmaceuticals due to the complexity of clinical trials and regulatory requirements, but anticipates increased government support for pediatric drug development[73]. Investor Relations - The company held over ten large-scale conference calls with analysts and investors, demonstrating its commitment to investor relations management[45]. - The company emphasizes the importance of reading the full report, particularly the section on risks and countermeasures[5]. Miscellaneous - The company did not undergo an audit for the semi-annual financial report[99]. - There were no significant litigation or arbitration matters during the reporting period[101]. - The company reported no major related party transactions in daily operations[104].